Nurix Therapeutics Inc (NRIX)
15.40
-0.50
(-3.14%)
USD |
NASDAQ |
May 16, 16:00
15.38
-0.02
(-0.10%)
After-Hours: 20:00
Nurix Therapeutics Revenue (Quarterly): 16.58M for Feb. 29, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| February 29, 2024 | 16.58M |
| November 30, 2023 | 15.16M |
| August 31, 2023 | 18.47M |
| May 31, 2023 | 30.68M |
| February 28, 2023 | 12.68M |
| November 30, 2022 | 6.783M |
| August 31, 2022 | 10.79M |
| May 31, 2022 | 11.43M |
| February 28, 2022 | 9.621M |
| November 30, 2021 | 7.396M |
| Date | Value |
|---|---|
| August 31, 2021 | 10.25M |
| May 31, 2021 | 7.091M |
| February 28, 2021 | 5.011M |
| November 30, 2020 | 6.689M |
| August 31, 2020 | 4.085M |
| May 31, 2020 | 4.182M |
| February 29, 2020 | 2.864M |
| November 30, 2019 | 1.862M |
| August 31, 2019 | 10.58M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.862M
Minimum
Nov 2019
30.68M
Maximum
May 2023
10.12M
Average
9.621M
Median
Feb 2022
Revenue (Quarterly) Benchmarks
| Gilead Sciences Inc | 6.686B |
| ALX Oncology Holdings Inc | -- |
| Vanda Pharmaceuticals Inc | 47.46M |
| GlycoMimetics Inc | -- |
| Immunic Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -41.52M |
| Total Expenses (Quarterly) | 61.80M |
| EPS Diluted (Quarterly) | -0.76 |
| Enterprise Value | 726.98M |
| Profit Margin (Quarterly) | -250.3% |
| Earnings Yield | -17.29% |
| Normalized Earnings Yield | -17.29 |